Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment

Trial Profile

Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Prasugrel
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms ISAR-REACT5
  • Most Recent Events

    • 10 Mar 2017 Planned End Date changed from 1 Oct 2018 to 1 Jan 2021.
    • 10 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2019.
    • 25 Nov 2013 Planned end date changed from 1 Nov 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top